Aust, Carlotta

[["dc.bibliographiccitation.firstpage","86"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","95"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: (1) To perform a 9-year study of abstinence, lapse, and relapse in 180 chronic alcoholic patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence. Method: This prospective open treatment study evaluates the long-term course of drinking outcomes and AD use of 180 chronic alcoholics consecutively admitted from 1993 to 2002. Subsamples are compared for (1) sham-AD versus verum-AD (disulfiram/calcium carbimide), (2) coped lapses versus finally detrimental lapses versus malignant relapses, and (3) AD use for 13 to 20 versus {.extbackslash}textgreater 20 months. Results: In this 9-year study, the cumulative probability of not having relapsed was 0.52, and that of not having consumed any alcohol was 0.26. Despite long-term use, disulfiram/calcium carbimide was well tolerated. Patients on sham-AD (due to contraindications to verum-AD) showed higher cumulative abstinence probability than patients on verum (S {.extbackslash}textequals 0.86 vs. S {.extbackslash}textequals 0.49, p {.extbackslash}textequals 0.03). Detrimental lapses and malignant relapses occurred earlier than successfully coped lapses (p {.extbackslash}textless 0.001); patients with detrimental lapse and with malignant relapse had rewer days of AD intake and less subsequent days without AD than patients with coped lapse (p {.extbackslash}textless 0.001). The cumulative abstinence probability was S {.extbackslash}textequals 0.75 for patients with long-term intake compared with S {.extbackslash}textequals 0.50 for patients who stopped AD between months 13 and 20 (p {.extbackslash}textless 0.001). Conclusions: An abstinence rate of {.extbackslash}textgreater 50{.extbackslash}textpercent in this 9-year study strongly supports the concept of comprehensive, long-term outpatient treatment of alcoholics. Supervised, guided intake of AD, also over extended periods, can be used as a predominantly psychologically acting ingredient of successful alcoholism therapy."],["dc.identifier.doi","10.1111/j.1530-0277.2006.00013.x"],["dc.identifier.gro","3150523"],["dc.identifier.pmid","16433735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7295"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0145-6008"],["dc.title","Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","708"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Psychiatric Services"],["dc.bibliographiccitation.lastpage","712"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Kuefner, Heinrich"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2021-06-01T10:47:52Z"],["dc.date.available","2021-06-01T10:47:52Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: A prospective four-year study examined which components of addiction severity predicted time to relapse among 112 adults with chronic alcoholism who participated in a comprehensive outpatient treatment program. Methods: Recruited from emergency, inpatient, and outpatient facilities, patients were admitted into the program consecutively between March 1998 and June 2002. Alcohol abstinence was carefully monitored for four years from admission by regular contacts and urine and blood analyses. Alcoholism characteristics and personality disorders were assessed with structured interviews and the International Diagnostic Checklists for Personality Disorders. Results: Among a variety of potential variables, only presence of a personality disorder and chronicity of addiction were independently associated with a decrease of cumulative four-year abstinence probability. Conclusions: Their high predictive values suggest that chronicity and personality disorder rank among the most important characteristics of addiction severity."],["dc.identifier.doi","10.1176/ps.2006.57.5.708"],["dc.identifier.gro","3150525"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85746"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1557-9700"],["dc.relation.issn","1075-2730"],["dc.subject","addiction severity; relapse; alcoholism treatment; personality disorder; prediction; addiction chronicity; 2006; Alcohol Rehabilitation; Alcoholism; Personality Disorders; Relapse (Disorders); Severity (Disorders); Chronicity (Disorders)"],["dc.title","Personality Disorder and Chronicity of Addiction as Independent OutcomePredictors in Alcoholism Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","195"],["dc.bibliographiccitation.issue","3-4"],["dc.bibliographiccitation.journal","Metabolic Brain Disease"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Herrmann, Manfred"],["dc.contributor.author","Sirén, Anna-Leena"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2004"],["dc.description.abstract","With the increased life expectancy in western industrialized countries, the incidence and prevalence of brain diseases dramatically increased. Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability. However, targeted effective therapies for treatment of these diseases are lacking. Even more frustrating is the fact that we do not yet clearly understand the basic mechanisms underlying the disease processes in these conditions. We propose a hypothesis of loss of neuronal function via a final common deleterious pathway in this clinically very heterogeneous disease group. This review presents a novel neuroprotective concept for treatment of brain disease: Erythropoietin (EPO). EPO is a natural body-own-protein hormone that has been used for treatment of anemia for more than a decade. The neuroprotective approach using EPO in brain disease represents a totally new frontier. The “Göttingen EPO-stroke trial” represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a neuroprotective strategy for a chronic brain disease."],["dc.identifier.gro","3150507"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7279"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0885-7490"],["dc.subject","EPO; stroke; schizophrenia; treatment; regeneration."],["dc.title","Erythropoietin: Novel approaches to neuroprotection in human brain disease"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","619"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","635"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Jahn, Henriette"],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Barth, Ulrike"],["dc.contributor.author","Sieg, Sonja"],["dc.contributor.author","Maul, Oliver"],["dc.contributor.author","Galwas, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Brunner, Edgar"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Henn, Fritz"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2004"],["dc.description.abstract","It is far from clear how comorbidity changes during alcoholism treatment. This study investigates: (1) the course of comorbid Axis I disorders in chronic alcoholics over 2 years of controlled abstinence in the outpatient long-term intensive therapy for alcoholics (OLITA) and (2) the effect of comorbid Axis I and II disorders in this group of patients on subsequent drinking outcome over a four-year follow-up. This prospective treatment study evaluates psychiatric variables of 89 severely affected chronic alcohol dependent patients on admission (t1), month 6 (t2), 12 (t3) and 24 (t4). Drinking outcomes have been analyzed from 1998 to 2002. On admission, 61.8% of the patients met criteria for a comorbid Axis I disorder, 63.2% for a comorbid personality disorder. Axis I disorders remit from t1 (59.0% ill), t2 (38.5%), t3 (28.2%) to t4 (12.8%) (p<0.0001). Anxiety disorders remit more slowly from t1 (43.6%) to t3 (20.5%, p=0.0086), whereas mood disorders remit early between t1 (23.1%) and t2 (5.1%, p=0.0387) with a slight transient increase at t3 (10.3%). During the four-year follow-up, the cumulative probability of not having relapsed amounts to 0.59. Two predictors have a strong negative impact on abstinence probability: number of inpatient detoxifications (p=0.0013) and personality disorders (p=0.0106). The present study demonstrates a striking remission of comorbid Axis I disorders upon abstinence during comprehensive long-term outpatient alcoholism treatment. The presence of an Axis II rather than an Axis I disorder on admission strongly predicts drinking outcome over a four-year follow-up"],["dc.identifier.doi","10.1016/j.jpsychires.2004.04.007"],["dc.identifier.gro","3150506"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0022-3956"],["dc.subject","Outpatient alcoholism treatment; Chronic alcohol dependence; Prognosis; Comorbid personality disorders; Chronicity; Chronic psychiatric illness"],["dc.title","Substantial decrease of psychiatric comorbidity in chronic alcoholics upon integrated outpatient treatment - results of a prospective study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","75"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Gesprächspsychotherapie und Personzentrierte Beratung"],["dc.bibliographiccitation.lastpage","84"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Reinhold, Jennifer"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Mahlke, Kristin"],["dc.contributor.author","Galwas, Claudia"],["dc.contributor.author","Barth, U."],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Haase, A."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Kroner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:45:47Z"],["dc.date.available","2017-09-07T11:45:47Z"],["dc.date.issued","2003"],["dc.identifier.gro","3150459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7225"],["dc.language.iso","de"],["dc.notes.status","zu prüfen"],["dc.title","Therapeutenrotation - erfolgreich für Alkoholkranke, erleichternd für Therapeuten : Therapieprozess} bei ALITA (Ambulante Langzeit - Intensivtherapie für Alkoholkranke) : Multiple Beziehungsgestaltung in der integrativen Therapie chronisch psychisch kranker Menschen"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Reinhold, J."],["dc.contributor.author","Jahn, Holger"],["dc.contributor.author","Mahlke, K."],["dc.contributor.author","Galwas, C."],["dc.contributor.author","Barth, U."],["dc.contributor.author","Aust, C."],["dc.contributor.author","Kroner-Herwig, B."],["dc.contributor.author","Brunner, E."],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Henn, Fritz A."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:36:48Z"],["dc.date.available","2018-11-07T10:36:48Z"],["dc.date.issued","2003"],["dc.format.extent","271"],["dc.identifier.isi","000186262800313"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45409"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","The course of psychiatric comorbidity in chronic alcoholics and its impact on abstinence during 4-year follow-up of integrated outpatient treatment"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","206"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","220"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Hinze-Selch, D."],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Knolle-Veentjer, S."],["dc.contributor.author","Wilms, S."],["dc.contributor.author","Heinz, G."],["dc.contributor.author","Erdag, S."],["dc.contributor.author","Jahn, H."],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Ritzen, M."],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Wagner, M."],["dc.contributor.author","Schneider, U."],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Huber, Martin"],["dc.contributor.author","Czernik, Adelheid"],["dc.contributor.author","Pollmacher, T."],["dc.contributor.author","Maier, Wolfgang"],["dc.contributor.author","Sirén, A-L."],["dc.contributor.author","Klosterkötter, J."],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Aldenhoff, Josef B."],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:24Z"],["dc.date.available","2017-09-07T11:46:24Z"],["dc.date.issued","2007"],["dc.description.abstract","Schizophrenia is increasingly recognized as a neurodevelopmental disease with an additional degenerative component, comprising cognitive decline and loss of cortical gray matter. We hypothesized that a neuroprotective/neurotrophic add-on strategy, recombinant human erythropoietin (rhEPO) in addition to stable antipsychotic medication, may be able to improve cognitive function even in chronic schizophrenic patients. Therefore, we designed a double-blind, placebo-controlled, randomized, multicenter, proof-of-principle (phase II) study. This study had a total duration of 2 years and an individual duration of 12 weeks with an additional safety visit at 16 weeks. Chronic schizophrenic men (N=39) with defined cognitive deficit (greater than or equal to1 s.d. below normal in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)), stable medication and disease state, were treated for 3 months with a weekly short (15 min) intravenous infusion of 40 000 IU rhEPO (N=20) or placebo (N=19). Main outcome measure was schizophrenia-relevant cognitive function at week 12. The neuropsychological test set (RBANS subtests delayed memory, language–semantic fluency, attention and Wisconsin Card Sorting Test (WCST-64) – perseverative errors) was applied over 2 days at baseline, 2 weeks, 4 weeks and 12 weeks of study participation. Both placebo and rhEPO patients improved in all evaluated categories. Patients receiving rhEPO showed a significant improvement over placebo patients in schizophrenia-related cognitive performance (RBANS subtests, WCST-64), but no effects on psychopathology or social functioning. Also, a significant decline in serum levels of S100B, a glial damage marker, occurred upon rhEPO. The fact that rhEPO is the first compound to exert a selective and lasting beneficial effect on cognition should encourage new treatment strategies for schizophrenia."],["dc.identifier.doi","10.1038/sj.mp.4001907"],["dc.identifier.gro","3150509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7281"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","1359-4184"],["dc.subject","S100B; plasticity; neuropsychology; psychopathology; high-dose EPO"],["dc.title","Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]